Summing up 100 years of asthma

Diamant, Zuzana; Boot, J. D.; Virchow, J. Christian

doi:10.1016/j.rmed.2006.12.004

Cited by 65 publications

(50 citation statements)

References 147 publications

(152 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, to our knowledge, there are no reports on the antiasthmatic activity of Samchulkunbi-tang . Patients with chronic asthma who take antiasthmatic drugs (including corticosteroids) for a long and indefinite time may develop serious side effects [17]. The present study was designed to determine if SCTE has anti-inflammatory and antiasthmatic effects in a mouse model of OVA-induced airway inflammation.…”

Section: Introductionmentioning

confidence: 99%

A water extract of Samchulkunbi-tang attenuates airway inflammation by inhibiting inos and MMP-9 activities in an ovalbumin-induced murine asthma model

Lee

Shin

Lim

et al. 2012

BMC Complement Altern Med

View full text Add to dashboard Cite

BackgroundIn this study, we investigated the effect of Samchulkunbi-tang water extract (SCTE) in an established mouse model of ovalbumin (OVA)-induced allergic asthma. The effects of SCTE on the production of Th1 and Th2 cytokines, eotaxin, and total and OVA-specific immunoglobulin E, inducible nitric oxide synthase expression, and matrix metalloproteinase-9 activity were measured.MethodsMice were sensitized on days 0 and 14 with an intraperitoneal injection of 20 μg ovalbumin (OVA) emulsified in 2 mg aluminum hydroxide in 200 μL PBS buffer. On days 21, 22, and 23, mice received an airway exposure to OVA (1%, w/v, in PBS) for 1 h. SCTE was administered orally to mice at doses of 200 and 400 mg/kg per day from days 18 to 23.ResultsSCTE reduced the number of inflammatory cells, cytokines, and chemokines in bronchoalveolar lavage fluids and iNOS expression and MMP-9 activity in mouse lung tissue. Histological studies using hematoxylin & eosin and periodic acid-schiff staining showed that SCTE substantially inhibited OVA-induced inflammatory cell infiltration in lung tissue and goblet cell hyperplasia in the airway. SCTE also reduced IL-4 and IL-13 expression in concanavalin-A-stimulated splenocytes. These results were similar to those obtained with montelukast as a positive control.ConclusionsCollectively, these results suggest that SCTE may be an effective oral treatment for allergic airway inflammation by virtue of its anti-inflammatory activity.

show abstract

Section: Introductionmentioning

confidence: 99%

A water extract of Samchulkunbi-tang attenuates airway inflammation by inhibiting inos and MMP-9 activities in an ovalbumin-induced murine asthma model

Lee

Shin

Lim

et al. 2012

BMC Complement Altern Med

View full text Add to dashboard Cite

show abstract

“…Os corticosteróides, antihistamínicos estabilizadores de membrana de mastócitos, inibidores de 5-lipoxigenase e CysLTant constituem classes de fármacos anti-inflamatórios utilizados no tratamento da asma (Figura 3). 22 Embora, a grande maioria dos pacientes asmáticos possam ser adequadamente tratados pelo uso regular da associação entre corticóides e agonistas β 2 adrenérgicos inalados, cerca de 5-10% da população mundial desenvolvem a chamada asma crônica severa e não respondem ao tratamento farmacológico disponível, contribuindo para o elevado índice de mortalidade associado a esta enfermidade. [23][24][25] Ao longo das duas últimas décadas inúmeros esforços de pesquisa foram dedicados à identificação de novas alternativas terapêuticas, mais eficazes e seguras, para o tratamento da asma.…”

Section: -21unclassified

LASSBio^®'s contribution in the development of novel antiasthmatic prototypes drug candidates

Lima¹,

Lima²

2009

Revista Virtual De Química

View full text Add to dashboard Cite

Abstract:In this paper will be described the physiopathological aspects of asthma and the main results obtained by the Laboratório de Avaliação e Síntese de Substâncias Bioativas (LASSBio ® ) in the discovery of novel antiasthmatic prototypes drug candidates, using physiological approach as an strategy to rational drug design.keywords: asthma, physiological approach, LASSBio-552, LASSBio-596, symbiotic ResumoNeste artigo serão tratados os aspectos fisiopatológicos da asma e descritos os principais resultados obtidos pelo Laboratório de Avaliação e Síntese de Substâncias Bioativas (LASSBio®) na descoberta de novos candidatos a protótipos de fármacos antiasmáticos, através do emprego da abordagem fisiológica como estratégia de planejamento racional. palavras-chave: asma, abordagem fisiológica, simbiótico

show abstract

“…Phosphodiesterase inhibition is an old concept in the treatment of COPD which has been already described by Hirsch and colleagues in 1922 [13]. However, the application of the prototypic non-selective phosphodiesterase (PDE)-inhibitors, aminophylline and theophylline, has been limited by many drug-interactions and a narrow dose-range, causing many dose-dependent, mostly cardiovascular and gastrointestinal side effects.…”

Section: Introductionmentioning

confidence: 99%

PDE4-inhibitors: A novel, targeted therapy for obstructive airways disease

Diamant

Spina

2011

Pulmonary Pharmacology & Therapeutics

Self Cite

View full text Add to dashboard Cite

SummaryRoflumilast is a selective once daily, oral phosphodiesterase-4 inhibitor that has recently been registered in all European Union countries as novel targeted therapy for COPD, while FDA approval for the USA market is expected in 2011. In several phase III trials in patients with moderate to (very) severe COPD and in patients with symptoms of chronic bronchitis and recurrent exacerbations, roflumilast showed sustained clinical efficacy by improving lung function and by reducing exacerbation rates. These beneficial effects have also been demonstrated when added to long-acting bronchodilators (both LABA and LAMA), underscoring the anti-inflammatory activity of roflumilast in COPD. Pooled data analysis showed overall mild to moderate, mostly self-limiting adverse events, mainly consisting of nausea, diarrhea and weight loss. In this review we discuss the results of the 4 registration studies showing promising effects of roflumilast in COPD and provide an overview of the topics that still need to be addressed. keywords: PDE4-inhibitor, roflumilast, clinical trials, chronic obstructive airways disease 3

show abstract

Summing up 100 years of asthma

Cited by 65 publications

References 147 publications

A water extract of Samchulkunbi-tang attenuates airway inflammation by inhibiting inos and MMP-9 activities in an ovalbumin-induced murine asthma model

A water extract of Samchulkunbi-tang attenuates airway inflammation by inhibiting inos and MMP-9 activities in an ovalbumin-induced murine asthma model

LASSBio^®'s contribution in the development of novel antiasthmatic prototypes drug candidates

PDE4-inhibitors: A novel, targeted therapy for obstructive airways disease

Contact Info

Product

Resources

About

Summing up 100 years of asthma

Cited by 65 publications

References 147 publications

A water extract of Samchulkunbi-tang attenuates airway inflammation by inhibiting inos and MMP-9 activities in an ovalbumin-induced murine asthma model

A water extract of Samchulkunbi-tang attenuates airway inflammation by inhibiting inos and MMP-9 activities in an ovalbumin-induced murine asthma model

LASSBio®'s contribution in the development of novel antiasthmatic prototypes drug candidates

PDE4-inhibitors: A novel, targeted therapy for obstructive airways disease

Contact Info

Product

Resources

About

LASSBio^®'s contribution in the development of novel antiasthmatic prototypes drug candidates